FDA and CBD
There has been a grey zone in the relationship between the FDA and the CBD industry since its beginnings. It’s of great importance to be on track with the most recent guidance of the agency that regulates the production and distribution of all cannabis derivatives, like CBD and any other hemp-related products.
Regarding cannabis policy, early in 2020, the White House reviewed the federal plans for marijuana and CBD research. The FDA submitted a cannabis guidance draft that was recently published, that will impact the CBD industry. For more information, “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research”. Lawmakers and stakeholders have been putting a great deal of pressure on the FDA to develop a regulation that lets CBD products be marketed lawfully.
Will CBD products be considered dietary supplements by the FDA?
According to hemp industry specialists, recent regulations will not affect the CBD industry, but it’s not a sure fact that recommendations will become rules. One outstanding issue was that over the counter edibles will be addressed by the current regulations. The FDA has said that guidance represents its current thinking on topics relevant to scientific research and the development of drugs containing compounds derived from cannabis. Featured documents of FDA guidance on Hemp and CBD treat the process for ingestibles in the form of dietary supplements. But considering the current COVID-19 situation, guidance on ingestibles will be postponed for a while.